Antitumor activity of the protein kinase inhibitor 1-(β-D-2′-deoxyribofuranosyl)-4,5,6,7-tetrabromo-1H-benzimidazole in breast cancer cell linesBMC CANCERIF3.42022-10-155OAAI
IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine NeoplasmsPHARMACEUTICALSIF4.82020-10-294OAAI
Impact of Aromatic Ring Count on the Ability to Participate in Attractive Interactions. Crystal Structure (X-ray) and Solid State Computational (DFT/QTAIM/RDS/Hirshfeld-surfaces) Study of 1,4-di(2-phenyl-1H-imidazol-4-yl)benzene. A Potential Nanotechnology Intrinsic ComponentCRYSTAL GROWTH & DESIGNIF3.42015-09-306PREAI
Isothiourea derivatives and CK2 inhibitors - a potential proapoptotic and cytostatic agents against astroglial tumours in vitroEUROPEAN JOURNAL OF CANCERIF7.12015-09-010PREAI
Zinc finger oxidation of Fpg/Nei DNA glycosylases by 2-thioxanthine: biochemical and X-ray structural characterizationNUCLEIC ACIDS RESEARCHIF13.12014-08-209OAAI
Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potentialCELLULAR AND MOLECULAR LIFE SCIENCESIF6.22014-01-1854OA
Modified tetrahalogenated benzimidazoles with CK2 inhibitory activity are active against human prostate cancer cells LNCaP in vitroBIOORGANIC & MEDICINAL CHEMISTRYIF32012-07-0119PRE
Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cellsCANCER LETTERSIF10.12012-02-0129OAAI
CK2α and CK2α′ subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivativesEUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92012-01-0133PREAI
Synthesis and Antimicrobial and Nitric Oxide Synthase Inhibitory Activities of Novel Isothiourea DerivativesARCHIVES OF PHARMACAL RESEARCHIF7.52010-07-0621PREAI
Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitroCELL AND TISSUE RESEARCHIF2.92010-04-0618PREAI
Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2BIOORGANIC & MEDICINAL CHEMISTRYIF32009-10-0165OAAI
Structural studies of 4,5,6,7-tetrabromobenzimidazole derivatives by means of solid-state 13C, 15N NMR spectroscopy and DFT calculationsJOURNAL OF MOLECULAR STRUCTUREIF4.72009-01-019PREAI
The selectivity of inhibitors of protein kinase CK2: an updateBIOCHEMICAL JOURNALIF4.32008-10-15242OA
Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2LEUKEMIAIF13.42006-11-0255PREAI
Synthesis and antimycobacterial activity of 2-substituted halogenobenzimidazolesEUROPEAN JOURNAL OF MEDICINAL CHEMISTRYIF5.92005-02-01100PREAI
Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazoleJOURNAL OF MEDICINAL CHEMISTRYIF6.82004-11-02193PREAI
Synthesis, and antiprotozoal and antibacterial activities of S-substituted 4,6-dibromo- and 4,6-dichloro-2-mercaptobenzimidazolesEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCESIF4.72004-02-0169PREAI
Polyhalogenobenzimidazoles: Synthesis and their inhibitory activity against casein kinasesBIOORGANIC & MEDICINAL CHEMISTRYIF32003-09-0166PREAI
Effect of gamma-irradiation on cladribine and cladribine-containing biodegradable copolymersJOURNAL OF CONTROLLED RELEASEIF11.52003-05-019PRE